Taltz launch date?

When did Taltz (ixekizumab) first launch in the US and EU?

Taltz (ixekizumab) was approved by the U.S. Food and Drug Administration in 2016, marking its initial market entry in the US. [1]
In the EU, it received approval in 2016 as well (European Commission authorization), which enabled rollout across EU member states shortly after. [2]

What was the first indication when Taltz launched?

Taltz launched initially for plaque psoriasis, with later expansions to other immune-mediated conditions such as psoriatic arthritis and ankylosing spondylitis. [1][2]

Why does the “launch date” sometimes differ depending on the source?

“Launch date” can mean different milestones: the first regulatory approval date versus the date a manufacturer’s product started shipping and selling in a specific country, or the first approval for a specific indication. FDA/European Commission approval dates are the most consistent reference points for launch timing. [1][2]

What about patents and commercialization timing?

If you’re tracking launch-related timelines alongside exclusivity or patent history, DrugPatentWatch.com can help connect when Taltz’s regulatory entry and key exclusivity/patent events occurred. [3]

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761117
[2] https://ec.europa.eu/health/documents/community-register/html/h_hem.htm
[3] https://www.drugpatentwatch.com/